Advertisement

ADVERTISEMENT

Multiple Myeloma

Conference Coverage
Ixazomib plus Pomalidomide and Dexamethasone Shows Promise in R/R MM
11/23/2021
Adding ixazomib to pomalidomide and dexamethasone treatment was found to be well-tolerated and a promising treatment option for patients with relapsed and refractory multiple myeloma.
Adding ixazomib to pomalidomide and dexamethasone treatment was found to be well-tolerated and a promising treatment option for patients with relapsed and refractory multiple myeloma.
Adding ixazomib to pomalidomide...
11/23/2021
Oncology
Dr Mounzer Agha
Videos
BCMA-Directed CAR-T Therapy Yields “Early and Deep” Responses in Patients With MM
08/10/2021
Mounzer Agha, MD, shares data from a phase 2 study of ciltacabtagene autoleucel in patients with progressive MM who received up to 3 prior lines of therapy, the data of which were presented at ASCO 2021.
Mounzer Agha, MD, shares data from a phase 2 study of ciltacabtagene autoleucel in patients with progressive MM who received up to 3 prior lines of therapy, the data of which were presented at ASCO 2021.
Mounzer Agha, MD, shares data...
08/10/2021
Oncology
Dr Philippe Moreau
Videos
Daratumumab Maintenance Improves PFS for Newly Diagnosed MM
07/30/2021
Philippe Moreau, MD, discusses the phase 3 CASSIOPEIA study on daratumumab maintenance plus VTd in patients with newly diagnosed MM.
Philippe Moreau, MD, discusses the phase 3 CASSIOPEIA study on daratumumab maintenance plus VTd in patients with newly diagnosed MM.
Philippe Moreau, MD, discusses...
07/30/2021
Oncology
Videos
Surbhi Sidana, MD, Discusses MGTA-145 Plus Plerixafor for Same-Day HSC Mobilization in MM
07/09/2021
Surbhi Sidana, MD, discusses a phase 2 study of MGTA-145 plus plerixafor for same-day HSC mobilization for autologous transplant in patients with MM. These data were presented at the 2021 ASCO Annual Meeting.
Surbhi Sidana, MD, discusses a phase 2 study of MGTA-145 plus plerixafor for same-day HSC mobilization for autologous transplant in patients with MM. These data were presented at the 2021 ASCO Annual Meeting.
Surbhi Sidana, MD, discusses a...
07/09/2021
Oncology
Dr
Videos
Jeff Kutok, MD, PhD, on Targeting SETD2 in the Treatment of MM
06/28/2021
Dr Kutok discusses preclinical data which were presented at the EHA2021 Virtual Congress that support the targeting of SEDT2 in patients with MM.
Dr Kutok discusses preclinical data which were presented at the EHA2021 Virtual Congress that support the targeting of SEDT2 in patients with MM.
Dr Kutok discusses preclinical...
06/28/2021
Oncology
Videos
Amrita Krishnan, MD, FACP, Talks Teclistamab for Patients With MM
06/09/2021
Dr Krishnan shares findings from a phase 3 trial of teclistamab therapy for relapsed/refractory MM. These data were presented at the 2021 ASCO Annual Meeting.
Dr Krishnan shares findings from a phase 3 trial of teclistamab therapy for relapsed/refractory MM. These data were presented at the 2021 ASCO Annual Meeting.
Dr Krishnan shares findings from...
06/09/2021
Oncology
Jesus Berjeda
Podcasts
Talquetamab Well Tolerated in Relapsed/Refractory MM
06/08/2021
Jesus Berdeja, MD, shares findings from a phase 1 study of talquetamab therapy for relapsed/refractory MM. These data are being presented at the 2021 ASCO Annual Meeting.
Jesus Berdeja, MD, shares findings from a phase 1 study of talquetamab therapy for relapsed/refractory MM. These data are being presented at the 2021 ASCO Annual Meeting.
Jesus Berdeja, MD, shares...
06/08/2021
Oncology
Dr Usmani
Videos
BCMA-Directed CAR-T Therapy Yields Durable Responses in Heavily Pretreated R/R MM
06/08/2021
Saad Usmani, MD, shares findings from the CARTITUDE-1 study of ciltacabtagene autoleucel therapy for patients with R/R MM. These data are being presented at the 2021 ASCO Annual Meeting.
Saad Usmani, MD, shares findings from the CARTITUDE-1 study of ciltacabtagene autoleucel therapy for patients with R/R MM. These data are being presented at the 2021 ASCO Annual Meeting.
Saad Usmani, MD, shares findings...
06/08/2021
Oncology
dr rossi
Videos
Dr Rossi Talks Lenalidomide, Melphalan as Effective Conditioning Regimen for ASCT in R/R MM
06/04/2021
Dr Rossi discusses a study on a combination conditioning regimen for ASCT in R/R MM, the findings of which are being presented at the 2021 ASCO Annual Meeting.
Dr Rossi discusses a study on a combination conditioning regimen for ASCT in R/R MM, the findings of which are being presented at the 2021 ASCO Annual Meeting.
Dr Rossi discusses a study on a...
06/04/2021
Oncology
dr nishihori
Videos
Taiga Nishihori, MD, Discusses Ixazomib Therapy After AlloHCT for High-Risk MM
06/04/2021
Taiga Nishihori, MD, shares findings from a trial of ixazomib maintenance after alloHCT in patients with high-risk MM. These data were presented at the 2021 ASCO Annual Meeting.
Taiga Nishihori, MD, shares findings from a trial of ixazomib maintenance after alloHCT in patients with high-risk MM. These data were presented at the 2021 ASCO Annual Meeting.
Taiga Nishihori, MD, shares...
06/04/2021
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

March 23 ⁠–⁠ March 24
April 27 ⁠–⁠ April 28
Great Debates & Updates in Diabetic Foot
November 30 ⁠–⁠ December 2
AIBD logo
November 27 ⁠–⁠ November 29
Psych Congress Primary Care Online Series
December 12 ⁠–⁠ December 13
May 13 ⁠–⁠ May 14
February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use